Illustration of a patient with a pelvic tumour. The image on the right shows...
Illustration of a patient with a pelvic tumour. The image on the right shows contrast-enhanced CT images used to manually segment the tumour (dashed line). Using spatial radiomic feature extraction and generation of habitat maps (middle image), three tumour habitats are feasible and highlighted in blue, red, and green, respectively. The third-from-right figure shows the ultrasound image with the co-registered CT-based tumour segmentation (dashed line). The right figure shows the CT scan overlaying the ultrasound plane, with the habitat maps highlighted in colour. The ultrasound images correspond to a different plane orientation with respect to the two rightmost panels

Image source: Beer et al., Urogenital 2020 (CC-BY 4.0)

News • CT & ultrasound fusion

‘Virtual biopsies’ could replace tissue biopsies in the future

A new advanced computing technique using routine medical scans to enable doctors to take fewer, more accurate tumour biopsies, has been developed by cancer researchers at the University of Cambridge.

This is an important step towards precision tissue sampling for cancer patients to help select the best treatment. In future the technique could even replace clinical biopsies with ‘virtual biopsies’, sparing patients invasive procedures. The research published in European Radiology shows that combining computed tomography (CT) scans with ultrasound images creates a visual guide for doctors to ensure they sample the full complexity of a tumour with fewer targeted biopsies.

Capturing the patchwork of different types of cancer cell within a tumour – known as tumour heterogeneity – is critical for selecting the best treatment because genetically-different cells may respond differently to treatment. Most cancer patients undergo one or several biopsies to confirm diagnosis and plan their treatment. But because this is an invasive clinical procedure, there is an urgent need to reduce the number of biopsies taken and to make sure biopsies accurately sample the genetically-different cells in the tumour, particularly for ovarian cancer patients.

High grade serous ovarian (HGSO) cancer, the most common type of ovarian cancer, is referred to as a ‘silent killer’ because early symptoms can be difficult to pick up. By the time the cancer is diagnosed, it is often at an advanced stage, and survival rates have not changed much over the last 20 years. But late diagnosis isn’t the only problem. HGSO tumours tend to have a high level of tumour heterogeneity and patients with more genetically-different patches of cancer cells tend to have a poorer response to treatment.

The accuracy of the CT/US fusion was associated with the tumour volume and was...
The accuracy of the CT/US fusion was associated with the tumour volume and was higher for pelvic compared to omental tumours. The dice similarity coefficient (DSC) was used to assess the accuracy of the CT/US fusion. The DSC was higher for the pelvic (larger) compared to that for the omental (smaller) tumours that yielded a low DSC. Dashed line, CT segmentation; solid line, US segmentation

Image source: Beer et al., Urogenital 2020 (CC-BY 4.0)

Professor Evis Sala from the Department of Radiology, co-lead CRUK Cambridge Centre Advanced Cancer Imaging Programme, leads a multi-disciplinary team of radiologists, physicists, oncologists and computational scientists using innovative computing techniques to reveal tumour heterogeneity from standard medical images. This new study, led by Professor Sala, involved a small group of patients with advanced ovarian cancer who were due to have ultrasound-guided biopsies prior to starting chemotherapy.

This study provides an important milestone towards precision tissue sampling. We are truly pushing the boundaries in translating cutting edge research to routine clinical care

Evis Sala

For the study, the patients first had a standard-of-care CT scan. A CT scanner uses x-rays and computing to create a 3D image of the tumour from multiple image ‘slices’ through the body. The researchers then used a process called radiomics – using high-powered computing methods to analyse and extract additional information from the data-rich images created by the CT scanner – to identify and map distinct areas and features of the tumour. The tumour map was then superimposed on the ultrasound image of the tumour and the combined image used to guide the biopsy procedure. By taking targeted biopsies using this method, the research team reported that the diversity of cancer cells within the tumour was successfully captured.

Co-first author Dr Lucian Beer, from the Department of Radiology and CRUK Cambridge Centre Ovarian Cancer Programme, said of the results: “Our study is a step forward to non-invasively unravel tumour heterogeneity by using standard-of-care CT-based radiomic tumour habitats for ultrasound-guided targeted biopsies.” Co-first author Paula Martin-Gonzalez, from the Cancer Research UK Cambridge Institute and CRUK Cambridge Centre Ovarian Cancer Programme, added: “We will now be applying this method in a larger clinical study.” Professor Sala said: “This study provides an important milestone towards precision tissue sampling. We are truly pushing the boundaries in translating cutting edge research to routine clinical care.”


Source: © University of Cambridge (CC-BY 4.0)

08.01.2021

Related articles

Photo

News •

Philips partners with the Stockholm County Council

Royal Philips today announced that it has signed a partnership agreement with the Stockholm County Council (SCC) to jointly innovate in health care.

Photo

Article •

Turbulences in ultrasound

Ultrasound expands its role in cardiac imaging with disruptive applications. Fasten your seat belt. Cardiac diagnostics is entering a zone of turbulence. Manufacturers of leading systems continue to…

Photo

Article •

Molecular US therapy, computer diagnosis and customized medication

Which technological advancements can we expect to see in the field of medical technology? How well can diagnosis and therapy be customized for each patient?

Related products

Subscribe to Newsletter